Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
NCT00939991
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
48
Enrollment
OTHER
Sponsor class
Conditions
Brain Tumor
Glioblastoma
Interventions
DRUG:
Vorinostst/Bevacizumab/Temozolomide
Sponsor
Katy Peters
Collaborators
[object Object]
[object Object]